|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Belluco C, Nitti D, Frantz M, Toppan P,
Basso D, Plebani M, Lise M and Jessup JM: Interleukin-6 blood level
is associated with circulating carcinoembryonic antigen and
prognosis in patients with colorectal cancer. Ann Surg Oncol.
7:133–138. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Komoda H, Tanaka Y, Honda M, Matsuo Y,
Hazama K and Takao T: Interleukin-6 levels in colorectal cancer
tissues. World J Surg. 22:895–898. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Galizia G, Orditura M, Romano C, Lieto E,
Castellano P, Pelosio L, Imperatore V, Catalano G, Pignatelli C and
De Vita F: Prognostic significance of circulating IL-10 and IL-6
serum levels in colon cancer patients undergoing surgery. Clin
Immunol. 102:169–178. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schneider MR, Hoeflich A, Fischer JR, Wolf
E, Sordat B and Lahm H: Interleukin-6 stimulates clonogenic growth
of primary and metastatic human colon carcinoma cells. Cancer Lett.
151:31–38. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Becker C, Fantini MC, Schramm C, Lehr HA,
Wirtz S, Nikolaev A, Burg J, Strand S, Kiesslich R, Huber S, et al:
TGF-beta suppresses tumor progression in colon cancer by inhibition
of IL-6 trans-signaling. Immunity. 2:491–501. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Becker C, Fantini MC, Wirtz S, Nikolaev A,
Lehr HA, Galle PR, Rose-John S and Neurath MF: IL-6 signaling
promotes tumor growth in colorectal cancer. Cell Cycle. 4:217–220.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dowdall JF, Winter DC, Andrews E, Laug WE,
Wang JH and Redmond HP: Soluble interleukin 6 receptor (sIL-6R)
mediates colonic tumor cell adherence to the vascular endothelium:
a mechanism for metastatic initiation? J Surg Res. 107:1–6. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Heinrich PC, Behrmann I, Haan S, Hermanns
HM, Müller-Newen G and Schaper F: Principles of interleukin
(IL)-6-type cytokine signalling and its regulation. Biochem J.
374:1–20. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bromberg J and Darnell JE Jr: The role of
STATs in transcriptional control and their impact on cellular
function. Oncogene. 19:2468–2473. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Aggarwal BB, Kunnumakkara AB, Harikumar
KB, Gupta SR, Tharakan ST, Koca C, Dey S and Sung B: Signal
transducer and activator of transcription-3, inflammation, and
cancer: how intimate is the relationship? Ann NY Acad Sci.
1171:59–76. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Darnell JE Jr: STATs and gene regulation.
Science. 277:1630–1635. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zushi S, Shinomura Y, Kiyohara T, Miyazaki
Y, Kondo S, Sugimachi M, Higashimoto Y, Kanayama S and Matsuzawa Y:
STAT3 mediates the survival signal in oncogenic ras-transfected
intestinal epithelial cells. Int J Cancer. 78:326–330. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Masuda M, Suzui M, Yasumatu R, Nakashima
T, Kuratomi Y, Azuma K, Tomita K, Komiyama S and Weinstein IB:
Constitutive activation of signal transducers and activators of
transcription 3 correlates with cyclin D1 overexpression and may
provide a novel prognostic marker in head and neck squamous cell
carcinoma. Cancer Res. 62:3351–3355. 2002.
|
|
15
|
Bromberg J and Wang TC: Inflammation and
cancer: IL-6 and STAT3 complete the link. Cancer Cell. 15:79–80.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kusaba T, Nakayama T, Yamazumi K, Yakata
Y, Yoshizaki A, Inoue K, Nagayasu T and Sekine I: Activation of
STAT3 is a marker of poor prognosis in human colorectal cancer.
Oncol Rep. 15:1445–1451. 2006.PubMed/NCBI
|
|
17
|
Lin Q, Lai R, Chirieac LR, Li C, Thomazy
VA, Grammatikakis I, Rassidakis GZ, Zhang W, Fujio Y, Kunisada K,
Hamilton SR and Amin HM: Constitutive activation of JAK3/STAT3 in
colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3
signaling induces apoptosis and cell cycle arrest of colon
carcinoma cells. Am J Pathol. 167:969–980. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xiong H, Zhang Z, Tian X, Sun D, Liang Q,
Zhang Y, Lu R, Chen Y and Fang J: Inhibition of JAK1, 2/STAT3
signaling induces apoptosis, cell cycle arrest, and reduces tumor
cell invasion in colorectal cancer cells. Neoplasia. 10:287–297.
2008.PubMed/NCBI
|
|
19
|
Endo TA, Masuhara M, Yokouchi M, Suzuki R,
Sakamoto H, Mitsui K, Matsumoto A, Tanimura S, Ohtsubo M, Misawa H,
et al: A new protein containing an SH2 domain that inhibits JAK
kinases. Nature. 387:921–924. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hilton DJ, Richardson RT, Alexander WS,
Viney EM, Willson TA, Sprigg NS, Starr R, Nicholson SE, Metcalf D
and Nicola NA: Twenty proteins containing a C-terminal SOCS box
form five structural classes. Proc Natl Acad Sci USA. 95:114–119.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Naka T, Narazaki M, Hirata M, Matsumoto T,
Minamoto S, Aono A, Nishimoto N, Kajita T, Taga T, Yoshizaki K, et
al: Structure and function of a new STAT-induced STAT inhibitor.
Nature. 387:924–929. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Starr R, Willson TA, Viney EM, Murray LJ,
Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA
and Hilton DJ: A family of cytokine-inducible inhibitors of
signalling. Nature. 387:917–921. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
He B, You L, Uematsu K, Zang K, Xu Z, Lee
AY, Costello JF, McCormick F and Jablons DM: SOCS-3 is frequently
silenced by hypermethylation and suppresses cell growth in human
lung cancer. Proc Natl Acad Sci USA. 100:14133–14138. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Oshimo Y, Kuraoka K, Nakayama H, Kitadai
Y, Yoshida K, Chayama K and Yasui W: Epigenetic inactivation of
SOCS-1 by CpG island hypermethylation in human gastric carcinoma.
Int J Cancer. 112:1003–1009. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sutherland KD, Lindeman GJ, Choong DY,
Wittlin S, Brentzell L, Phillips W, Campbell IG and Visvader JE:
Differential hypermethylation of SOCS genes in ovarian and breast
carcinomas. Oncogene. 23:7726–7733. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rigby RJ, Simmons JG, Greenhalgh CJ,
Alexander WS and Lund PK: Suppressor of cytokine signaling 3
(SOCS3) limits damage-induced crypt hyper-proliferation and
inflammation-associated tumorigenesis in the colon. Oncogene.
26:4833–4841. 2007. View Article : Google Scholar
|
|
27
|
Gustin DM and Brenner DE: Chemoprevention
of colon cancer: current status and future prospects. Cancer
Metastasis Rev. 21:323–348. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gorlick R and Bertino JR: Drug resistance
in colon cancer. Semin Oncol. 26:606–611. 1999.
|
|
29
|
Longley DB, Allen WL and Johnston PG: Drug
resistance, predictive markers and pharmacogenomics in colorectal
cancer. Biochim Biophys Acta. 1766:184–196. 2006.PubMed/NCBI
|
|
30
|
Boose G and Stopper H: Genotoxicity of
several clinically used topoisomerase II inhibitors. Toxicol Lett.
116:7–16. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Newman DJ, Cragg GM and Snader KM: The
influence of natural products upon drug discovery. Nat Prod Rep.
17:215–234. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gordaliza M: Natural products as leads to
anticancer drugs. Clin Transl Oncol. 9:767–776. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lin JM, Chen YQ, Wei LH, Chen XZ, Xu W,
Hong ZF, Sferra TJ and Peng J: Hedyotis Diffusa Willd
extract induces apoptosis via activation of the
mitochondrion-dependent pathway in human colon carcinoma cells. Int
J Oncol. 37:1331–1338. 2010.
|
|
34
|
Chinese Pharmacopoeia Commission.
Pharmacopoeia of the Peoples Republic of China. 1. Chinese Medical
Science and Technology Press; Beijing: pp. 573–575. 2010
|
|
35
|
Xu YY and Yu EX: Clinical analysis of the
effect of Pien Tze Huang in treatment of 42 patients with moderate
or advanced liver cancer. Shanghai J Tradit Chin Med. 12:4–5.
1994.
|
|
36
|
Gu ZX: Therapeutical observation of
advanced colon cancer. Chin Tradit Patent Med. 15:231993.
|
|
37
|
Lin JM, Wei LH, Chen YQ, Liu XX, Hong ZF,
Sferra TJ and Peng J: Pien Tze Huang-induced apoptosis in human
colon cancer HT-29 cells is associated with regulation of the Bcl-2
family and activation of caspase 3. Chin J Integr Med. 17:685–690.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhuang QC, Hong F, Shen AL, Zheng LP, Zeng
JW, Lin W, Chen YQ, Sferra TJ, Hong ZF and Peng J: Pien Tze Huang
inhibits tumor cell proliferation and promotes apoptosis via
suppressing the STAT3 pathway in a colorectal cancer mouse model.
Int J Oncol. 40:1569–1574. 2012.PubMed/NCBI
|
|
39
|
Schmitz J, Weissenbach M, Haan S, Heinrich
PC and Schaper F: SOCS3 exerts its inhibitory function on
interleukin-6 signal transduction through the SHP2 recruitment site
of gp130. J Biol Chem. 275:12848–12856. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sommer U, Schmid C, Sobota RM, Lehmann U,
Stevenson NJ, Johnston JA, Schaper F, Heinrich PC and Haan S:
Mechanisms of SOCS3 phosphorylation upon interleukin-6 stimulation.
Contributions of Src- and receptor-tyrosine kinases. J Biol Chem.
280:31478–31488. 2005. View Article : Google Scholar : PubMed/NCBI
|
